Germline Pathogenic Variants in BRCA1 and BRCA2: Malignancies Beyond Female Breast and Ovarian Cancers

J Clin Oncol. 2022 May 10;40(14):1590-1594. doi: 10.1200/JCO.22.00003. Epub 2022 Mar 14.

Authors

Sari Lieberman¹, Hadar Goldvaser^{2

3}, Ephrat Levy-Lahad^{1

3}

Affiliations

¹ Medical Genetics Institute, Shaare Zedek Medical Center, Jerusalem, Israel.
² Institute of Oncology, Shaare Zedek Medical Center, Jerusalem, Israel.
³ Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.

PMID: 35286153
DOI: 10.1200/JCO.22.00003

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

BRCA1 Protein / genetics
BRCA2 Protein / genetics
Breast Neoplasms* / genetics
Female
Genetic Predisposition to Disease
Germ Cells / pathology
Germ-Line Mutation
Humans
Ovarian Neoplasms* / genetics
Ovarian Neoplasms* / pathology

Substances

BRCA1 Protein
BRCA1 protein, human
BRCA2 Protein
BRCA2 protein, human